{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T05:13:00Z","timestamp":1775538780144,"version":"3.50.1"},"reference-count":35,"publisher":"Oceanside Publications Inc.","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Asthma management has been revolutionized by the introduction and expansion of biologic therapies. Since the approval of omalizumab for allergic asthma in 2003, six additional biologics with an asthma indication have been FDA-approved, and several more are in\n late-phase development. The clinical challenge is that all of these therapies reduce exacerbations, but asthma exacerbations are difficult to predict. A subgroup of 20\u201040% of biologic-treated patients will achieve asthma remission, or near remission depending on the criteria used, during\n biologic therapy, an ideal outcome. For the remaining 60\u201080% of treated patients, the benefits are evident but usually less defined or quantifiable. Symptoms often improve, but patient-reported outcomes lack precision to verify efficacy. All biologic therapies reduce exacerbations by\n an average of 50%; they do not eliminate exacerbations for most patients. In long-term, unblinded, safety trials, the majority of treated subjects have zero to one exacerbation per year. Thus, for an individual patient, assessing response and predicting response can be problematic, and strategies\n for addressing suboptimal responses are not standardized.\n                    <jats:bold>Methods:<\/jats:bold>\n                    This article summarizes a potential approach to use when biologic therapy in adults with asthma is, or appears to be, insufficiently effective.\n                    <jats:bold>Results:<\/jats:bold>\n                    The major points are: 1) set expectations\n prior to therapy to facilitate decision making and do not expect remission or near remission depending on criteria used; 2) reassess the source of symptoms and findings with the possibility that the asthma diagnosis is not accurate or co-morbidities are the major contributors to the clinical\n presentation; 3) evaluate adherence with both small molecule therapy (i.e. inhaled controller therapy) and with the biologic regimen if administered in-home; 4) change the biologic to an alternative biologic, generally affecting a different pathway.\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    This strategy\n is not a guarantee of success but may assist in clinical decision-making.\n                  <\/jats:p>","DOI":"10.2500\/aap.2026.47.260003","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T04:35:38Z","timestamp":1773722138000},"page":"78-84","source":"Crossref","is-referenced-by-count":1,"title":["What to do when your adult patient with severe asthma does not respond to a biologic"],"prefix":"10.2500","volume":"47","author":[{"given":"Dennis K.","family":"Ledford","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1355","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S2213-2600(24)00383-7","article-title":"Asthma: epidemiology, risk factors, and opportunities for prevention and treatment","volume":"13","author":"Jayasooriya","year":"2025","journal-title":"Lancet Respir Med"},{"key":"B2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12890-017-0409-3","article-title":"The frequency of asthma exacerbations and healthcare utilization in patients with asthma from the UK and USA","volume":"17","author":"Suruki","year":"2017","journal-title":"BMC Pulm Med"},{"key":"B3","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/j.jaip.2024.05.034","article-title":"Risk factors for acute asthma exacerbations in adults with mild asthma","volume":"12","author":"Chen","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B4","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1136\/thoraxjnl-2017-210650","article-title":"Exacerbation risk and characterization of the UK\u2019s asthma population from infants to old age","volume":"73","author":"Bloom","year":"2018","journal-title":"Thorax"},{"key":"B5","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1183\/09031936.05.00037905","article-title":"Risk factors of frequent exacerbations in difficult-to-treat asthma","volume":"26","author":"ten Brinke","year":"2005","journal-title":"Eur Respir J"},{"key":"B6","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1183\/09031936.00075614","article-title":"Medication adherence and the risk of severe asthma exacerbations: a systematic review","volume":"45","author":"Engelkes","year":"2015","journal-title":"Eur Respir J"},{"key":"B7","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1016\/S0140-6736(25)01625-3","article-title":"Anti-cytokine biologics for asthma in adults","volume":"406","author":"Israel","year":"2025","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jaip.2019.11.020","article-title":"Diagnosis and management of T2-high asthma","volume":"8","author":"Coverstone","year":"2020","journal-title":"J Allergy Clin Immunol Prac"},{"key":"B9","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1080\/02770903.2022.2103427","article-title":"Severe non-atopic asthma: omalizumab can reduce severe asthma exacerbations","volume":"60","author":"Melscoet","year":"2023","journal-title":"J Asthma"},{"key":"B10","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in adults with uncontrolled asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2147\/JAA.S452386","article-title":"Quality of life improvements with biologic initiation among subspecialist-treated US patients with severe asthma","volume":"17","author":"Soong","year":"2024","journal-title":"J Asthma Allergy"},{"key":"B12","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.anai.2022.06.012","article-title":"Biologic use and outcomes among adults with severe asthma treated by US subspecialists.","volume":"129","author":"Panettieri","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B13","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jaip.2019.08.050","article-title":"Dupilumab efficacy in patients with uncontrolled, moderate-to-severe allergic asthma","volume":"8","author":"Corren","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B14","doi-asserted-by":"crossref","first-page":"100957","DOI":"10.1016\/j.waojou.2024.100957","article-title":"Effect of biologic therapies on quality of life in severe asthma: findings from the PRISM study","volume":"17","author":"Rhyou","year":"2024","journal-title":"World Allergy Organ J"},{"key":"B15","doi-asserted-by":"crossref","first-page":"14799731211043530","DOI":"10.1177\/14799731211043530","article-title":"Comparison of the sensitivity of patient-reported outcomes for detecting the benefit of biologics in severe asthma","volume":"18","author":"Hyland","year":"2021","journal-title":"Chron Respir Dis"},{"key":"B16","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.jaci.2025.05.034","article-title":"Current data on biologics: evaluating clinical remission in asthma","volume":"156","author":"Pavord","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B17","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.chest.2023.10.046","article-title":"Clinical responses and remission in patients with severe asthma treated with biologic therapies","volume":"165","author":"Hansen","year":"2024","journal-title":"Chest"},{"key":"B18","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1164\/rccm.202308-1436OC","article-title":"Prevalence, diagnostic utility and associated characteristics of bronchodilator responsiveness","volume":"209","author":"Beasley","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"B19","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jaci.2024.11.006","article-title":"Asthma and respiratory comorbidities","volume":"155","author":"Ledford","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B20","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.jaip.2024.01.028","article-title":"Living with asthma and vocal cord dysfunction\/inducible laryngeal obstruction: \u201cI just can\u2019t get air in.\u201d","volume":"12","author":"Majellano","year":"2024","journal-title":"J Allergy Clin Immunol Prac"},{"key":"B21","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/resp.70055","article-title":"A global achievement: introducing the inducible laryngeal dysfunction\/vocal cord dysfunction toolkit\u2014a free global, peer\u2010reviewed clinical resource","volume":"30","author":"Leong","year":"2025","journal-title":"Respirology"},{"key":"B22","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.jaci.2023.06.007","article-title":"Diagnosis of vocal cord dysfunction\/inducible laryngeal obstruction: an International Delphi Consensus Study","volume":"152","author":"Leong","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B23","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1080\/02770903.2019.1645169","article-title":"Prevalence and predictors of adherence to controller therapy in adult patients with severe\/difficult-to-treat asthma: a systematic review and meta-analysis","volume":"57","author":"Hassan","year":"2020","journal-title":"J Asthma"},{"key":"B24","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.anai.2023.07.017","article-title":"Real-world severe asthma biologic administration and adherence differs by biologic: CHRONICLE study results","volume":"131","author":"Ledford","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B25","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2147\/JAA.S328653","article-title":"Real world biologic use and switch patterns in severe asthma: data from the International Severe Asthma Registry and the US CHRONICLE study","volume":"15","author":"Menzies-Gow","year":"2022","journal-title":"J Asthma Allergy"},{"key":"B26","doi-asserted-by":"crossref","first-page":"1052339","DOI":"10.3389\/falgy.2022.1052339","article-title":"Real-world clinical outcomes of asthma patients switched from reslizumab to mepolizumab or benralizumab","volume":"3","author":"Walsh","year":"2023","journal-title":"Front Allergy"},{"key":"B27","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3390\/arm92020014","article-title":"Advancing care in severe asthma: the art of switching biologics","volume":"92","author":"Dragonieri","year":"2024","journal-title":"Adv Respir Med"},{"key":"B28","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1164\/rccm.201707-1323OC","article-title":"Weight-adjusted intravenous reslizumab in severe asthma with inadequate response to fixed-dose subcutaneous mepolizumab","volume":"197","author":"Mukherjee","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"B29","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.2147\/JAA.S543815","article-title":"Patients with higher exacerbation burden and eosinophil counts are more likely to require multiple biologics for asthma control","volume":"18","author":"Brown","year":"2025","journal-title":"J Asthma Allergy"},{"key":"B30","doi-asserted-by":"crossref","first-page":"765747","DOI":"10.3389\/fimmu.2021.765747","article-title":"How to prevent and mitigate hypersensitivity reactions to biologicals induced by anti-drug antibodies?","volume":"12","author":"Vultaggio","year":"2021","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"crossref","first-page":"220","DOI":"10.7861\/clinmedicine.17-3-220","article-title":"Developments in therapy with monoclonal antibodies and related proteins","volume":"17","author":"Shepard","year":"2017","journal-title":"Clin Med (Lond)"},{"key":"B32","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3390\/biomedicines13020299","article-title":"Anti-drug antibody response to therapeutic antibodies and potential mitigation strategies","volume":"13","author":"Howard","year":"2025","journal-title":"Biomedicines"},{"key":"B33","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jaci.2018.09.033","article-title":"Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma","volume":"143","author":"Khatri","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B34","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1016\/j.jaip.2021.07.058","article-title":"Integrated safety and efficacy among patients receiving benralizumab for up to 5 years","volume":"9","author":"Korn","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B35","doi-asserted-by":"crossref","first-page":"2101499","DOI":"10.1183\/13993003.01499-2021","article-title":"ERS\/ATS technical standard on interpretive strategies for routine lung function tests","volume":"60","author":"Stanojevic","year":"2021","journal-title":"Eur Respir J"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2026\/00000047\/00000002\/art00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T04:32:39Z","timestamp":1775536359000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2026.47.260003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3,1]]}},"alternative-id":["1088-5412(20260301)47:2L.78;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2026.47.260003","relation":{},"ISSN":["1088-5412"],"issn-type":[{"value":"1088-5412","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,1]]}}}